RGNX REGENXBIO Inc.
Financings ·
REGENXBIO launched a $100 million stock offering on July 16, 2026 at $9.00 a share, below the $11.20 close. Its own preliminary estimate puts cash, cash equivalents and marketable securities at about $105.5 million on June 30, down from $150.5 million on March 31.
REGENXBIO opened an option exchange offer for non-executive employees on June 3, 2026, after stockholders approved it. Stockholders rejected a similar program for executives, and the company's 2025 annual report says the year's $193.9 million net loss and a going-concern doubt sit alongside $240.9 million of cash.
REGENXBIO started a stock option exchange for non-executive employees on June 3, 2026, after stockholders approved it at the May 29 annual meeting. Stockholders rejected a similar exchange for executives, with 21,021,531 votes against to 14,097,815 for.
REGENXBIO filed a prospectus supplement for up to $150 million of at-the-market stock sales through Leerink Partners. The filing warns of substantial doubt about its ability to continue as a going concern.
A REGENXBIO subsidiary signed a limited recourse royalty bond with an affiliate of HealthCare Royalty Management, repaid only from royalties. The company says the $150 million received at closing extends its cash runway into early 2027.
REGENXBIO Inc. describes itself as a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Its investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform to deliver functional genes that enable the production of therapeutic proteins or antibodies. Its named development partners are AbbVie, which collaborates on surabgene lomparvovec (sura-vec, ABBV-RGX-314), and Nippon Shinyaku Co., Ltd., which collaborates on RGX-121 (clemidsogene lanparvovec) and RGX-111. The text refers to a Complete Response Letter for RGX-121 and to clinical holds on RGX-111 and RGX-121 that must be resolved to the satisfaction of the FDA. The company runs clinical trials under names including AAVIATE, AFFINITY BEYOND, AFFINITY DUCHENNE, ALTITUDE, ASCENT, ATMOSPHERE, CAMPSIITE and NAAVIGATE. Its forward-looking statements name the ability to continue as a going concern and the impact of government-imposed tariffs on partnered product candidates among the factors that could affect results.
| Product or program | What it is | Stage |
|---|---|---|
| sura-vec (ABBV-RGX-314) | Gene therapy in a collaboration with AbbVie | |
| RGX-121 (clemidsogene lanparvovec) | Gene therapy in a collaboration with Nippon Shinyaku | Complete Response Letter received; clinical hold |
| RGX-111 | Investigational AAV gene therapy in a collaboration with Nippon Shinyaku | clinical hold |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $228.3 million | $208.5 million |
| Net income (loss) | -$193.9 million | -$227.1 million |
| Cash from operations | -$124.0 million | -$173.1 million |
| Cash and equivalents | $34.5 million | $57.5 million |
| Short-term investments | $195.6 million | $177.2 million |
Our latest story on this, dated Jun 3, 2026: "REGENXBIO starts stock option exchange offer for non-executive employees". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 16, 2026: "REGENXBIO prices $100 million stock offering at $9.00 a share". The story links the filing or release it is based on. Read the story.
REGENXBIO Inc. trades under the ticker RGNX on NASDAQ.
REGENXBIO Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:RB0; LS:A140E0; LSX:A140E0.
The SEC Central Index Key (CIK) for REGENXBIO Inc. is 1590877. Its filings are on SEC EDGAR.
66,013,192 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records REGENXBIO Inc. under United States.
Our directory classifies REGENXBIO Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for REGENXBIO Inc. is US75901B1070.
aibio.space lists REGENXBIO Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
REGENXBIO Inc. describes itself as a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Its investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform to deliver functional genes that enable the production of therapeutic proteins or antibodies.
sura-vec (ABBV-RGX-314): Gene therapy in a collaboration with AbbVie
RGX-121 (clemidsogene lanparvovec): Gene therapy in a collaboration with Nippon Shinyaku Stage: Complete Response Letter received; clinical hold.
REGENXBIO Inc. reported a net loss of $193.9 million for the fiscal year ended Dec 31, 2025, and used $124.0 million of cash in operations, per its annual report to the SEC.
$228.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.07,8.01). Source
Offered to buy back its own securities. SEC Form SC TO-I. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio